Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Gene therapy for dopamine replacement in Parkinson's disease.

In English

Författare

Summary, in English

The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this enzyme-replacement approach.

Publiceringsår

2009

Språk

Engelska

Sidor

2-2

Publikation/Tidskrift/Serie

Science Translational Medicine

Volym

1

Issue

2

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for the Advancement of Science (AAAS)

Ämne

  • Neurosciences

Status

Published

Forskningsgrupp

  • Neurobiology
  • Molecular Neuromodulation
  • Brain Repair and Imaging in Neural Systems (BRAINS)

ISBN/ISSN/Övrigt

  • ISSN: 1946-6242